File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Drug-eluting stents and balloons in peripheral arterial disease: Evidence so far

TitleDrug-eluting stents and balloons in peripheral arterial disease: Evidence so far
Authors
Issue Date2011
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/IJCP
Citation
International Journal Of Clinical Practice, 2011, v. 65 n. 6, p. 664-668 How to Cite?
AbstractRestenosis by myointimal hyperplasia after peripheral arterial angioplasty or stenting is a major problem limiting its long-term efficiency and patency, and may lead to recurrent symptoms. Drug-eluting devices which inhibit the proliferation of neo-intimal growth of vascular smooth muscle cells may prevent restenosis. The aim of this article is to examine the evidence in published literature on the use of drug-eluting devices in the treatment of peripheral arterial diseases. A systematic literature review was undertaken of all published literature on this subject using Medline and cross-referenced. All published relevant articles on the use of drug-eluting stents and balloons in peripheral arterial disease were used. Cochrane Central Register of Controlled Trials and electronic databases were also searched for on-going studies. Published results from randomised studies such as the SIROCCO I and II Trials and the THUNDER study, together with single cohort studies, are now available. There are on-going studies comparing drug-eluting and non-drug-eluting devices. Evidence from the published literature suggests that drug-eluting stents and balloons are safe and effective in preventing restenosis after peripheral angioplasty. However, drug-eluting devices are more expensive and many are limited to single-use only. It is anticipated that results from all the on-going studies may allow a meta-analysis to show whether these preliminary data can translate into a clinically applicable cost-effective strategy in combating restenosis after peripheral angioplasty or stenting. © 2011 Blackwell Publishing Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/135556
ISSN
2015 Impact Factor: 2.226
2015 SCImago Journal Rankings: 0.759
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChan, YCen_HK
dc.contributor.authorCheng, SWen_HK
dc.date.accessioned2011-07-27T01:37:06Z-
dc.date.available2011-07-27T01:37:06Z-
dc.date.issued2011en_HK
dc.identifier.citationInternational Journal Of Clinical Practice, 2011, v. 65 n. 6, p. 664-668en_HK
dc.identifier.issn1368-5031en_HK
dc.identifier.urihttp://hdl.handle.net/10722/135556-
dc.description.abstractRestenosis by myointimal hyperplasia after peripheral arterial angioplasty or stenting is a major problem limiting its long-term efficiency and patency, and may lead to recurrent symptoms. Drug-eluting devices which inhibit the proliferation of neo-intimal growth of vascular smooth muscle cells may prevent restenosis. The aim of this article is to examine the evidence in published literature on the use of drug-eluting devices in the treatment of peripheral arterial diseases. A systematic literature review was undertaken of all published literature on this subject using Medline and cross-referenced. All published relevant articles on the use of drug-eluting stents and balloons in peripheral arterial disease were used. Cochrane Central Register of Controlled Trials and electronic databases were also searched for on-going studies. Published results from randomised studies such as the SIROCCO I and II Trials and the THUNDER study, together with single cohort studies, are now available. There are on-going studies comparing drug-eluting and non-drug-eluting devices. Evidence from the published literature suggests that drug-eluting stents and balloons are safe and effective in preventing restenosis after peripheral angioplasty. However, drug-eluting devices are more expensive and many are limited to single-use only. It is anticipated that results from all the on-going studies may allow a meta-analysis to show whether these preliminary data can translate into a clinically applicable cost-effective strategy in combating restenosis after peripheral angioplasty or stenting. © 2011 Blackwell Publishing Ltd.en_HK
dc.languageengen_US
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/IJCPen_HK
dc.relation.ispartofInternational Journal of Clinical Practiceen_HK
dc.subject.meshAngioplasty, Balloon - methodsen_HK
dc.subject.meshAtherosclerosis - therapyen_HK
dc.subject.meshDrug-Eluting Stentsen_HK
dc.subject.meshEvidence-Based Medicineen_HK
dc.subject.meshHumansen_HK
dc.subject.meshIschemia - therapyen_HK
dc.subject.meshLeg - blood supplyen_HK
dc.subject.meshPeripheral Arterial Disease - therapyen_HK
dc.subject.meshRecurrenceen_HK
dc.titleDrug-eluting stents and balloons in peripheral arterial disease: Evidence so faren_HK
dc.typeArticleen_HK
dc.identifier.emailChan, YC: ycchan88@hkucc.hku.hken_HK
dc.identifier.emailCheng, SW: wkcheng@hkucc.hku.hken_HK
dc.identifier.authorityChan, YC=rp00530en_HK
dc.identifier.authorityCheng, SW=rp00374en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1742-1241.2011.02639.xen_HK
dc.identifier.pmid21564438-
dc.identifier.scopuseid_2-s2.0-79956068293en_HK
dc.identifier.hkuros188129en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-79956068293&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume65en_HK
dc.identifier.issue6en_HK
dc.identifier.spage664en_HK
dc.identifier.epage668en_HK
dc.identifier.isiWOS:000290488600009-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridChan, YC=27170769400en_HK
dc.identifier.scopusauthoridCheng, SW=7404684779en_HK
dc.identifier.citeulike9323935-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats